Meijer Chris J L M, Heideman Daniëlle A M, Berkhof Hans, Snijders Peter J F
Department of Pathology, Vrije Universiteit Medical Center, Amsterdam, Netherlands.
Immunol Lett. 2009 Feb 21;122(2):126-7. doi: 10.1016/j.imlet.2008.11.011. Epub 2008 Dec 25.
Based on the insight that cervical cancer is caused by high-risk human papillomavirus (hrHPV) types, two new directions of cervical cancer prevention have emerged: primary prevention by prophylactic vaccination against hrHPV types 16 and 18, and secondary prevention by cervical screening with HPV DNA testing. These "current views" elaborate on both prevention modes in the context of public health. It is argued that within the next decades using current vaccines the most effective way of prevention and control of cervical cancer requires an integrated vaccination-screening approach, including routine prophylactic vaccination to pre-pubertal women and adapted cervical screening for older women.
基于宫颈癌由高危型人乳头瘤病毒(hrHPV)引起这一认识,出现了两种新的宫颈癌预防方向:通过预防性接种针对16型和18型hrHPV的疫苗进行一级预防,以及通过HPV DNA检测进行宫颈筛查进行二级预防。这些“当前观点”在公共卫生背景下详细阐述了这两种预防模式。有人认为,在未来几十年内,使用现有疫苗预防和控制宫颈癌的最有效方法需要采取综合的疫苗接种-筛查方法,包括对青春期前女性进行常规预防性接种,以及对老年女性进行适应性宫颈筛查。